Risdiplam

PTC Therapeutics, Inc. (NASDAQ: PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform. The Thesis Risdiplam’s efficacy data compares...